Since they are highly rebated in 2026 and 2027 list is around 2026 net for employers, I would imagine little to no rebate in 2027
While innovation benefits patients, research and development investments are often factored into overall pricing strategies
Patients who fail to respond adequately to semaglutide often respond better to tirzepatide, not because of dose differences but because the dual mechanism addresses different pathways
Initial assessment typically includes reviewing medication adherence, hydration status, dietary habits, and concurrent medications
Patients should be advised that "GLP-1 probiotic" marketing claims are not FDA-evaluated and may be misleading
Initial studies in rats caused concerns over GLP-1 RAs causing thyroid cancer, but human studies are less clear on whether it is a concern.[ref] Decreased risk of substance abuse: A large 2026 study using data from the VA showed that GLP-1 RA drugs reduce the risk of developing a substance addiction (drugs, alcohol)